Loading
A phase 1/2 trial of Pembrolizumab in ovarian cancer and melanoma, run by BioInvent International AB, now recruiting.
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) is a phase 1/2 interventional study registered as NCT04752826 by BioInvent International AB, with 176 participants planned, started 2021-01-25 and due to reach its primary completion in 2026-12-31. Interventions recorded: BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection. Conditions listed: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BioInvent International, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares BioInvent International, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/